ERBB2 and breast carcinoma: Although the use of human epidermal growth factor receptor-2 (HER2) inhibitors is a frequent cause of cardiac dysfunction in breast cancer, the results indicate that HER2 inhibitor therapy and diabetes interact to potentiate their effects on cardiac dysfunction.